Total deal worth KRW 7 billion including upfront KRW 1 billion + milestones... 技术转让 of 角膜损伤 treatment candidate 'RCI001U' domestic production and commercialization rights... Phase 1 临床试验 planned this year
RudaCure announced on the 16th that it has signed a 对外许可 agreement worth KRW 7 billion with 翰林制药 for the 角膜溃疡 and 角膜损伤 treatment candidate 'RCI001U.'
Under the agreement, RudaCure will receive a total of KRW 7 billion from 翰林制药, including an upfront payment of KRW 1 billion plus milestones such as clinical approvals. 翰林制药 will hold domestic production and commercialization rights for RCI001U. RudaCure will receive double-digit royalties after commercialization.
Both companies plan to enter Phase 1 临床试验 for RCI001U within this year to expedite commercialization.
RCI001U is a 管线 derived from RCI001, RudaCure's existing 干眼症治疗药 candidate, the Rac1 inhibitor currently in development. This follows RudaCure's 技术转让 of the 干眼症治疗药 candidate RCI001 to 翰林制药 in 2021, with this deal covering an additional indication.
According to RudaCure, given that treatment drugs for 角膜损伤 are currently limited domestically, the 技术转让 of RCI001U is being made after completing third-party confirmatory 疗效 testing and non-clinical toxicology studies.
A RudaCure representative stated, "Through this additional indication 技术转让 agreement, we have strengthened our network with 翰林制药," adding, "We expect continuous collaboration to develop not only 干眼症 and 角膜损伤 treatments, but also various 眼科 treatments including 眼部 implants for 黄斑变性."
